[1] Habak C, Noreau A, Nagano-Saito A, et al. Dopamine trans-porter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's disease[J]. Brain, 2014, 137(Pt 11):3025-3035. [2] 彭岩, 殷盛明, 于德钦, 等. 早期帕金森病大鼠血清抗氧化能力降低[J]. 中国应用生理学杂志, 2011, 27(5):218-220. [3] Tansey MG, Frank-Cannon TC, McCoy MK, et al. McAlpine FE, Ruhn KA, Tran TA. Neuroinflammation in Parkinson's disease:is there sufficient evidence for mechanism-based in-terventional therapy[J]. Front Biosci, 2008, 13:709-717. [4] 闫颖, 赵咏梅. 脑源性神经营养因子与帕金森治疗研究进展[J]. 中国老年学杂志, 2011, 31(3):527-530. [5] Decressac M, Barker RA. Neuropeptide Y and its role in CNS disease and repair[J]. Exp Neurol, 2012, 238(2):265-272. [6] Morales-Medina JC, Dumont Y, Benoit CE, et al. Role of neuropeptide Y Y1 and Y2 receptors on behavioral despair in a rat model of depression with co-morbid anxiety[J]. Neu-ropharmacol, 2012, 62(1):200-208. [7] Brooks DJ. The early diagnosis of Parkinson's disease[J]. Ann Neurol, 1998, 44(3 Suppl 1):S10-18. [8] Na SJ, DiLella AG, Lis EV, et al. Stone DJ, Hess JF. Molecular profiling of a 6-hydroxydopamine model of Parkin-son's disease[J]. Neurochem Res, 2010, 35(5):761-72. [9] Yin SM, Yu DQ, Gao X, et al. Scorpion venom heat-resist ant protein decreases immunoreactivity of OX-42-positive mi-croglia cells in MPTP-treated mice[J]. Neural Regen Res, 2008, 3(9):967-970. [10] 殷盛明, 于德钦, 彭岩, 等. 神经元营养活性肽保护帕金森病大鼠的小胶质细胞机制[J]. 中草药, 2010, 41(11):20-24. [11] 于德钦, 殷盛明, 彭岩. 早期帕金森病大鼠线粒体损伤的研究[J]. 中风与神经疾病杂志, 2010, (06), 511-513. [12] Baquet ZC, Bickford PC, Jones KR. Brain-derived neu-rotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta[J]. J Neurosci. 2005, 25(26):6251-6259. [13] 牛平, 王耀山, 吕永利, 等. 脑源性神经营养因子对帕金森病大鼠黑质多巴胺能神经元的影响[J]. 中风与神经疾病杂志, 2000, 17(4). [14] 赵钢勇, 崔蕾, 高娟, 等. BDNF基因工程细胞对帕金森大鼠纹状体多巴胺及其代谢物影响的研究[J]. 中国应用生理学杂志, 2013, 29(1):82-85. [15] 胡春燕, 李英文. 神经肽Y(NPY)的生理功能研究进展[J]. 生物学杂志, 2011, 28(2):66-68. [16] Jenner P. Functional models of Parkinson's disease:a valu-able tool in the development of novel therapies[J]. Ann Neu-rol, 2008, 64(Suppl 2):S16-29. |